文献速递银屑病与炎症性皮肤病

古塞奇尤单抗治疗有色人种中重度头皮银屑病:VISIBLE试验B队列48周结果

Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2025-01-01

VISIBLE试验B队列纳入108例有色人种中重度头皮银屑病患者,随机3:1接受古塞奇尤单抗100mg或安慰剂。第16周古塞奇尤单抗组ss-IGA 0/1应答率68.4% vs 安慰剂11.5%(P<.001),PSSI 90应答率65.8% vs 3.8%(P<.001)。疗效和生活质量改善持续至第48周。

要点

  • 古塞奇尤单抗第16周ss-IGA 0/1达68.4%,安慰剂仅11.5%
  • 第48周PSSI和SSA平均改善分别达94.6%和94.8%
  • DLQI和PSSD症状评分改善持续至第48周

核心结论

  • 在有肤色谱系的中重度头皮银屑病患者中,古塞奇尤单抗治疗3次后多数患者实现显著头皮清除和生活质量改善,并持续至第48周。

研究设计与样本

  • 正在进行的3b期随机临床试验,在美国和加拿大45个中心纳入108例有色人种中重度头皮银屑病成人患者,按3:1随机接受古塞奇尤单抗100mg(n=81)或安慰剂(n=27)。
  • 古塞奇尤单抗在第0、4周及之后每8周给药;安慰剂组在第0、4、12周给药,第16、20周及之后每8周交叉至古塞奇尤单抗。
  • 数据收集时间为2022年9月至2024年6月,100例(92.6%)完成48周治疗。

主要发现

  • 第16周古塞奇尤单抗组(n=76)vs 安慰剂组(n=26):ss-IGA 0/1为68.4% vs 11.5%(P<.001);PSSI 90为65.8% vs 3.8%(P<.001);ss-IGA 0为57.9% vs 3.8%(P<.001);PSSI 100为59.2% vs 3.8%(P<.001)。
  • 基线头皮瘙痒NRS≥4者中,第16周NRS评分降低≥4分的比例:古塞奇尤单抗组69.4%(50/72)vs 安慰剂组24.0%(6/25)(P<.001)。
  • 第48周古塞奇尤单抗随机组PSSI和SSA平均(SD)百分比改善分别为94.6%(12.2%)和94.8%(16.2%),51例(67.1%)达到ss-IGA 0。
  • DLQI和PSSD症状评分最小二乘均值变化:古塞奇尤单抗组vs安慰剂组分别为-9.7(95%CI -11.1至-8.2)vs -2.2(95%CI -4.8至0.4)(P<.001)和-44.8(95%CI -50.6至-39.1)vs -8.3(95%CI -18.4至1.9)(P<.001),并持续至第48周。
  • 截至第16周,感染是最常见不良事件:古塞奇尤单抗组12例(14.8%),安慰剂组1例(3.7%)。

关键数值与推荐

  • 入组标准:有色人种成人,中重度头皮银屑病(SSA≥30%、PSSI≥12、ss-IGA≥3、至少1处非头皮斑块)。
  • 共同主要终点:第16周ss-IGA 0/1和PSSI 90(古塞奇尤单抗 vs 安慰剂)。
  • 主要次要终点包括ss-IGA 0、PSSI 100、PSSI和SSA较基线百分比变化、DLQI和PSSD症状评分变化、头皮瘙痒NRS评分降低≥4分。

临床怎么用

  • 对于有色人种中重度头皮银屑病患者,古塞奇尤单抗100mg可在第16周实现高比例头皮清除和瘙痒改善,并持续至第48周。
  • 治疗期间应关注感染不良事件,第16周前古塞奇尤单抗组感染发生率14.8%。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Varying hair textures and hair care practices contribute to nuances in clinical presentation and management of scalp psoriasis across diverse patient populations. Cohort B of the VISIBLE trial enrolled participants with moderate to severe scalp psoriasis and skin of color, across the skin-tone spectrum. OBJECTIVE: To evaluate efficacy, quality of life, and adverse event outcomes of guselkumab, 100 mg, among participants with moderate to severe scalp psoriasis and skin of color over 48 weeks. DESIGN, SETTING, AND PARTICIPANTS: This ongoing phase 3b, randomized clinical trial at 45 sites in the US and Canada enrolled adults with skin of color and moderate to severe scalp psoriasis (scalp surface area [SSA] ≥30%; Psoriasis Scalp Severity Index [PSSI] ≥12; scalp-specific Investigator's Global Assessment [ss-IGA] score ≥3; ≥1 nonscalp plaque). Data were collected from September 2022 to June 2024. INTERVENTIONS: Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0, 4, and every 8 weeks, or placebo at weeks 0, 4, and 12, then guselkumab at weeks 16, 20, and every 8 weeks. MAIN OUTCOMES AND MEASURES: Coprimary end points were ss-IGA score of 0 or 1 (ss-IGA 0/1) and 90% or greater improvement in PSSI (PSSI 90) at week 16 (guselkumab vs placebo). Major secondary end points included ss-IGA 0 (complete scalp clearance), PSSI 100, percentage changes from baseline in PSSI and SSA, changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms score, and 4-point or greater reduction in Scalp Itch Numeric Rating Scale (NRS) score. RESULTS: Of 108 participants (81 randomized to guselkumab; 27 randomized to placebo), 100 (92.6%) completed 48 weeks of treatment. The mean (SD) age overall was 42.5 (13.6) years, and 58 participants (56.9%) were male. At the week 16 primary end point, in the guselkumab (n = 76) vs placebo (n = 26) groups, respectively, response rates were as follows: ss-IGA 0/1, 68.4% (n = 52) vs 11.5% (n = 3) (P < .001); PSSI 90, 65.8% (n = 50) vs 3.8% (n = 1) (P < .001); ss-IGA 0, 57.9% (n = 44) vs 3.8% (n = 1) (P < .001); PSSI 100, 59.2% (n = 45) vs 3.8% (n = 1) (P < .001); 4-point or greater reduction in Scalp Itch NRS score (in those with a baseline score of at least 4), 69.4% (n = 50 of 72) vs 24.0% (n = 6 of 25) (P < .001). Guselkumab efficacy increased and was maintained through week 48, when guselkumab-randomized participants achieved mean (SD) percentage improvements in PSSI and SSA of 94.6% (12.2%) and 94.8% (16.2%), respectively, and 51 (67.1%) achieved ss-IGA 0. DLQI and PSSD symptoms score least-squares mean changes were -9.7 (95% CI, -11.1 to -8.2) vs -2.2 (95% CI, -4.8 to 0.4) (P < .001) and -44.8 (95% CI, -50.6 to -39.1) vs -8.3 (95% CI, -18.4 to 1.9) (P < .001), respectively, with sustained improvements through week 48. Through week 16, infections were the most common adverse events in the guselkumab (n = 12; 14.8%) and placebo (n = 1; 3.7%) groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, after 3 doses of guselkumab, most participants achieved significant scalp clearance and clinically meaningful quality-of-life improvements; improvements increased and were maintained through week 48. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05272150.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. McMichael A, Shahriari M, Stein Gold L, et al. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. JAMA Dermatol. 2025. PMID: 40560554. doi:10.1001/jamadermatol.2025.1849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。